Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Leukemia derived dendritic cells (LDCs) are functionally deficient and inferior to DC leukemia fusion cells as a tumor vaccine for AML

Rosenblatt J, Stone R, Lenahan C, Wu Z, Vasir B, DeAngelo DJ, Galinsky I, Miller K, Levine JD, Joyce R, Kufe D, Avigan D. Leukemia derived dendritic cells (LDCs) are functionally deficient and inferior to DC leukemia fusion cells as a tumor vaccine for AML. Blood. 2005; 106(11):782a.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.